Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB

• Published in: The New England journal of medicine Vol. 388; no. 1; pp. 89 - 91
• Main Authors: Imai, Masaki, Ito, Mutsumi, Kiso, Maki, Yamayoshi, Seiya, Uraki, Ryuta, Fukushi, Shuetsu, Watanabe, Shinji, Suzuki, Tadaki, Maeda, Ken, Sakai-Tagawa, Yuko, Iwatsuki-Horimoto, Kiyoko, Halfmann, Peter J., Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 05.01.2023
• Subjects: Antiviral agents; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Coronavirus; Coronaviruses; Correspondence; COVID-19; COVID-19 - virology; COVID-19 Drug Treatment; Disease transmission; Drugs; FDA approval; Humans; Infectious Disease; Infectious diseases; Medical research; Monoclonal antibodies; R&D; Research & development; RNA polymerase; SARS-CoV-2 - drug effects; Severe acute respiratory syndrome coronavirus 2; Treatment Outcome; Viral Infections; Japan

Neither bebtelovimab nor any mAb combinations tested neutralized the SARS-CoV-2 omicron subvariants BQ.1.1 and XBB, but remdesivir, molnupiravir, and nirmatrelvir were efficacious against both in vitro.